Targeting angiogenesis for the treatment of advanced melanoma

Oncology Reviews

Volumn 5, Issue 3, 2011, Pages 167-176

  Bafaloukos, Dimitrios J ^a   Linardou, Helena ^a  

^a METROPOLITAN HOSPITAL   (Greece)

Author keywords

Angiogenesis; Growth factors; Melanoma; VEGF inhibitors

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; AFLIBERCEPT; ALPHA INTERFERON; AXITINIB; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BATIMASTAT; BAY 12 95566; BEVACIZUMAB; BMS 58266; CARBOPLATIN; CILENGITIDE; ENTINOSTAT; ERLOTINIB; ETARACIZUMAB; EVEROLIMUS; GELATINASE A; GELATINASE B; IMATINIB; INCYCLINIDE; INTERLEUKIN 8; INTETUMUMAB; LENALIDOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PLACEBO; PLACENTAL GROWTH FACTOR; PROTEIN BCL 2; RAPAMYCIN; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANGIOGENESIS; BLOOD LEVEL; BREAST TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; COLORECTAL TUMOR; DIARRHEA; DOWNSTREAM PROCESSING; DRUG POTENTIATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FATIGUE; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY TUMOR; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN METASTASIS; UPREGULATION;

EID: 83255174966     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-011-0075-2     Document Type: Review

References (44)

1. Fecher LA, Cummings SD, Keefe MJ, Alani RM (2007) Toward a molecular classification of melanoma. J Clin Oncol 25:1606-1620 (Pubitemid 46733089)
2. Houghton AN, Legha S, Bajorin DF (1992) Chemotherapy for metastatic melanomas. In: Balch CM, Houghton AN, Milton SG,Sober AJ, Soong S (eds) Cutaneous melanoma, 2nd edn. Lippincott, Philadelphia, pp 458-508
3. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18 (Pubitemid 43261975)
4. Warren BA, Shubik P (1966) The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 15:464-478
5. Hubler WR Jr, Wolf JE Jr (1976) Melanoma. Tumor angiogenesis and human neoplasia. Cancer 38:187-192
6. Elder DE, Van Belle P, Elenitasas R, Halpern A, Guerry D (1996) Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 15:336-348 (Pubitemid 27197972)
7. Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, Herlyn M (1998) Molecular events in melanoma development and progression. Front Biosci 3:1005-1010
8. Tuthill RJ, Reed RI (2007) Failure of senescence in the dysplasia- melanoma sequence: demonstration using a tissue microarray and a revised paradigm for melanoma. Semin Oncol 34:467-475 (Pubitemid 350236313)
9. Wanebo HJ, Argiris A, Bergsland E et al (2006) Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev 25:279-292 (Pubitemid 43886403)
10. Gille J (2006) Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 15:175-186
11. Plum SM, Holaday JW, Ruiz A et al (2000) Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2- mediated angiogenesis and tumor development. Vaccine 19:1294-1303 (Pubitemid 32008298)
12. Bar-Eli M (1999) Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67:12-18 (Pubitemid 29037606)
13. Kuphal S, Bauer R, Bosserhoff AK (2005) Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24:195-222 (Pubitemid 40922795)
14. Luttun A, Autiero M, Tjwa M, Carmeliet P (2004) Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta 1654:79-94 (Pubitemid 38230933)
15. Hofmann UB, Westphal JR, Van Muijen GNP, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337-344
16. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11:5158-5166 (Pubitemid 41003701)
17. Schnaeker E-M, Ossig R, Ludwig T et al (2004) Microtubuledependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 64:8924-8931 (Pubitemid 39665499)
18. Varker KA, Biber JE, Kefauver C et al (2007) A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon a-2b in metastatic malignant melanoma. Ann Surg Oncol 14:2367-2376 (Pubitemid 47174913)
19. Perez DG, Suman VJ, Fitch TR et al (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment group study, N047A. Cancer 115:119-127
20. O'Day SJ, Kim KB, Sosman JA et al (2009) BEAM: a randomized Phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Eur J Cancer Suppl 7 (Abstract 23LBA)
21. Corrie P, Marshall A, East C et al (2009) Safety of adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence. 7th World Congress on Melanoma Vienna, 12-16 May 2009
22. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
23. Eisen T, Ahmad T, Flaherty KT et al (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95:581-586 (Pubitemid 44325897)
24. Hauschild A, Agarwala SS, Trefzer U et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823-2830
25. Eisen T, Ahmad T, Marais R et al (2005) Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma (abstract). Eur J Cancer Suppl 3:349
26. Eisen T, Marais R, Affolter A et al (2007) An open-label phase ii study of sorafenib and dacarbazine as first line therapy in patients with advanced melanoma (abstract). J Clin Oncol 25:8529
27. McDermott DF, Sosman JA, Gonzalez R et al (2008) Doubleblind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group. J Clin Oncol 26:2178-2185
28. Amaravadi R, Schuchter LM, McDermott DF et al (2007) Updated results of a randomized phase ii study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma (abstract). J Clin Oncol 25:8527
29. Fruehauf J, Lutzky J, McDermott D et al (2008) Axitinib (AG- 013736) in patients with metastatic melanoma: a Phase II study. J Clin Oncol 26 (Abstract 9006)
30. Sini P, Wyder L, Schnell C et al (2005) The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 11:4521-4532 (Pubitemid 40825643)
31. Wyman K, Spigel D, Puzanov I et al (2007) A multicenter Phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18S) (Abstract 8539)
32. Ugerel S, Hildenbrand R, Zimpfer A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398-1405 (Pubitemid 40705006)
33. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346 (Pubitemid 46630793)
34. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD et al (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257-264 (Pubitemid 46917693)
35. Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH, Tsujigiwa H, Tamamura R, Han KN, Nagai N (2008) C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452:27-32
36. Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-493 (Pubitemid 351990966)
37. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Krase A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-2051
38. Ishihara K, Saida T, Otsuka F, Yamazaki N (2008) Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 13:33-41 (Pubitemid 351326291)
39. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954 (Pubitemid 34716871)
40. A study to evaluate RAF265, an oral drug administered to subjects with locally advanced or metastatic melanoma. http://clinicaltrials.gov/ct2/show/ NCT00304525
41. Flaherty K, Puzanov I, Sosman J et al (2009) Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27 (15S) (Abstract 9000)
42. Adjei AA, Cohen RB, Franklin W et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146
43. Dummer R, Robert C, Chapman PB et al (2008) AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study (abstract). J Clin Oncol 26(Suppl):9033
44. Dutcher JP, Hudes G, Motzer R et al (2003) Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon-(IFN) to patients with advanced renal cell carcinoma (RCC) (abstract). Proc Am Soc Clin Oncol 22:213